Healthline

Side Effects of Emgality: What You Need to Know

Emgality’s most common side effect is a reaction at the injection site. This can cause itching, pain, skin discoloration, or swelling. Other possible side effects include high blood pressure and ...
FiercePharma

Lilly’s Emgality nabs third-to-market migraine nod but aims to be 'treatment of choice' in CGRP

Eli Lilly may not be first to the market with its next-gen migraine drug Emgality, but with an approval Thursday, the drugmaker still believes it can be the “treatment of choice” for migraine ...
Business Insider

Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine

INDIANAPOLIS, June 15, 2021 /PRNewswire/ -- To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to ...
Nasdaq

Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments

INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...
Nasdaq

FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...
Monthly Prescribing Reference

Migraine Prevention Treatment Emgality Gets FDA Approval

The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine. The Food and Drug ...